244 reports of this reaction
1.4% of all BRENTUXIMAB VEDOTIN reports
#20 most reported adverse reaction
WHITE BLOOD CELL COUNT DECREASED is the #20 most commonly reported adverse reaction for BRENTUXIMAB VEDOTIN, manufactured by SEAGEN INC.. There are 244 FDA adverse event reports linking BRENTUXIMAB VEDOTIN to WHITE BLOOD CELL COUNT DECREASED. This represents approximately 1.4% of all 18,008 adverse event reports for this drug.
Patients taking BRENTUXIMAB VEDOTIN who experience white blood cell count decreased should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
WHITE BLOOD CELL COUNT DECREASED is a less commonly reported adverse event for BRENTUXIMAB VEDOTIN, but still significant enough to appear in the safety profile.
In addition to white blood cell count decreased, the following adverse reactions have been reported for BRENTUXIMAB VEDOTIN:
The following drugs have also been linked to white blood cell count decreased in FDA adverse event reports:
WHITE BLOOD CELL COUNT DECREASED has been reported as an adverse event in 244 FDA reports for BRENTUXIMAB VEDOTIN. This does not prove causation, but indicates an association observed in post-market surveillance data.
WHITE BLOOD CELL COUNT DECREASED accounts for approximately 1.4% of all adverse event reports for BRENTUXIMAB VEDOTIN, making it a notable side effect.
If you experience white blood cell count decreased while taking BRENTUXIMAB VEDOTIN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.